Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.33 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | PKM | P14618 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4376376 | 0.86 | KDM4E (0.46) | KDM4EKMT2ACHRM2CHRM1EPHX2 | |
| SCHEMBL190916 | 0.86 | KDM4E (0.46) | KDM4EKMT2ACHRM2CHRM1EPHX2 | |
| Hydrochloric Acid SCHEMBL2249026 | 0.84 | KDM4E (0.45) | KDM4EKMT2ACHRM2CHRM1EPHX2 | |
| SCHEMBL19871799 | 0.81 | EPHX2 (0.33) | EPHX2 | |
| SCHEMBL15893901 | 0.79 | KDM4E (0.50) | KDM4EKMT2AEPHX2ALDH1A1MAPT | |
| Hydrochloric Acid SCHEMBL2595097 | 0.78 | KDM4E (0.48) | KDM4EKMT2AEPHX2ALDH1A1MAPT | |
| SCHEMBL9066588 | 0.75 | — | — | |
| SCHEMBL17582317 | 0.74 | KMT2A (0.37) | KDM4EKMT2ACHRM2CHRM1EPHX2 | |
| SCHEMBL13100462 | 0.73 | — | — | |
| SCHEMBL30135255 | 0.72 | KDM4E (0.42) | KDM4EKMT2AEPHX2ALDH1A1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9783527-B2 | Indazole ureas and method of use | ABBVIE INC. (US) | 2017-10-10 | — | — | US | disclosed |
| US-20160075692-A1 | Indazole Ureas and Method of Use | ABBVIE INC. (US) | 2016-03-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160075692-A1 | Indazole Ureas and Method of Use | SCN8A, SCN7A, SCN3A | KDM4E 2206/4885KMT2A 3943/4885CHRM2 197/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.